-5%
Rulicent contains Ruxolitinib, a kinase inhibitor that blocks Janus Associated Kinases (JAK1 and JAK2). These enzymes mediate signaling pathways for cytokines and growth factors essential for blood cell production and immune function. Dysregulated JAK1 and JAK2 signaling is a hallmark of myelofibrosis (MF), a type of myeloproliferative neoplasm (MPN). By inhibiting these pathways, Ruxolitinib helps reduce spleen size, lowers the number of JAK2V617F mutant cells in the spleen, and decreases inflammatory cytokines such as TNF-α and IL-6.
Myelofibrosis: Rulicent is prescribed for adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
Polycythemia Vera: Rulicent is used to treat polycythemia vera (PV) in adults who have not responded adequately to or cannot tolerate hydroxyurea.
Acute Graft-Versus-Host Disease (GVHD): Rulicent is indicated for treating steroid-refractory acute GVHD in adults and children aged 12 years and older.
Use this medication only under the guidance of a registered physician.
- Ruxolitinib is rapidly absorbed, with peak plasma concentrations occurring within 1–2 hours after oral administration. Its oral absorption rate is approximately 95%.
- The steady-state volume of distribution in MF and PV patients is around 72 L.
- The mean half-life of Ruxolitinib and its metabolites is about 5.8 hours, with an elimination half-life of approximately 3 hours.
- Protein Binding 97%, mainly to albumin.
- Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9.
- Ruxolitinib is primarily eliminated through metabolism, with 74% excreted in urine and 22% in feces. Less than 1% of the total excreted radioactivity is an unchanged drug.